Trial Profile
A Phase II Study Of GW572016 In Squamous Cell Carcinoma Of The Head And Neck (SCCHN)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 10 Jan 2014 Actual end date is changed to 1 December 2006 according to ClinicalTrials.gov record.
- 14 Apr 2009 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 22 Aug 2006 Status change